182 related articles for article (PubMed ID: 23394121)
1. Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology.
Fonseca MI; McGuire SO; Counts SE; Tenner AJ
J Neuroinflammation; 2013 Feb; 10():25. PubMed ID: 23394121
[TBL] [Abstract][Full Text] [Related]
2. C5L2: a controversial receptor of complement anaphylatoxin, C5a.
Li R; Coulthard LG; Wu MC; Taylor SM; Woodruff TM
FASEB J; 2013 Mar; 27(3):855-64. PubMed ID: 23239822
[TBL] [Abstract][Full Text] [Related]
3. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2.
Raby AC; Holst B; Davies J; Colmont C; Laumonnier Y; Coles B; Shah S; Hall J; Topley N; Köhl J; Morgan BP; Labéta MO
Eur J Immunol; 2011 Sep; 41(9):2741-52. PubMed ID: 21630250
[TBL] [Abstract][Full Text] [Related]
4. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Yuan J; Gou SJ; Huang J; Hao J; Chen M; Zhao MH
Arthritis Res Ther; 2012 Jun; 14(3):R140. PubMed ID: 22691190
[TBL] [Abstract][Full Text] [Related]
5. C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism.
Otto M; Hawlisch H; Monk PN; Müller M; Klos A; Karp CL; Köhl J
J Biol Chem; 2004 Jan; 279(1):142-51. PubMed ID: 14570896
[TBL] [Abstract][Full Text] [Related]
6. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease.
Ager RR; Fonseca MI; Chu SH; Sanderson SD; Taylor SM; Woodruff TM; Tenner AJ
J Neurochem; 2010 Apr; 113(2):389-401. PubMed ID: 20132482
[TBL] [Abstract][Full Text] [Related]
7. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74).
Cain SA; Monk PN
J Biol Chem; 2002 Mar; 277(9):7165-9. PubMed ID: 11773063
[TBL] [Abstract][Full Text] [Related]
8. C5L2 and C5aR interaction in adipocytes and macrophages: insights into adipoimmunology.
Poursharifi P; Lapointe M; Pétrin D; Devost D; Gauvreau D; Hébert TE; Cianflone K
Cell Signal; 2013 Apr; 25(4):910-8. PubMed ID: 23268185
[TBL] [Abstract][Full Text] [Related]
9. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.
Huber-Lang M; Sarma JV; Rittirsch D; Schreiber H; Weiss M; Flierl M; Younkin E; Schneider M; Suger-Wiedeck H; Gebhard F; McClintock SD; Neff T; Zetoune F; Bruckner U; Guo RF; Monk PN; Ward PA
J Immunol; 2005 Jan; 174(2):1104-10. PubMed ID: 15634936
[TBL] [Abstract][Full Text] [Related]
10. A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation.
Hao J; Wang C; Yuan J; Chen M; Zhao MH
PLoS One; 2013; 8(6):e66305. PubMed ID: 23785491
[TBL] [Abstract][Full Text] [Related]
11. Complement C5a receptors C5L2 and C5aR in renal fibrosis.
Martin IV; Bohner A; Boor P; Shagdarsuren E; Raffetseder U; Lammert F; Floege J; Ostendorf T; Weber SN
Am J Physiol Renal Physiol; 2018 Jan; 314(1):F35-F46. PubMed ID: 28903945
[TBL] [Abstract][Full Text] [Related]
12. C5L2, a nonsignaling C5A binding protein.
Okinaga S; Slattery D; Humbles A; Zsengeller Z; Morteau O; Kinrade MB; Brodbeck RM; Krause JE; Choe HR; Gerard NP; Gerard C
Biochemistry; 2003 Aug; 42(31):9406-15. PubMed ID: 12899627
[TBL] [Abstract][Full Text] [Related]
13. Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney.
van Werkhoven MB; Damman J; Daha MR; Krikke C; van Goor H; van Son WJ; Hillebrands JL; van Dijk MC; Seelen MA
Mol Immunol; 2013 Mar; 53(3):237-45. PubMed ID: 22960554
[TBL] [Abstract][Full Text] [Related]
14. Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway.
Cao Q; McIsaac SM; Stadnyk AW
Am J Physiol Cell Physiol; 2012 Jun; 302(12):C1731-40. PubMed ID: 22496247
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.
Fonseca MI; Ager RR; Chu SH; Yazan O; Sanderson SD; LaFerla FM; Taylor SM; Woodruff TM; Tenner AJ
J Immunol; 2009 Jul; 183(2):1375-83. PubMed ID: 19561098
[TBL] [Abstract][Full Text] [Related]
16. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques.
Vijayan S; Asare Y; Grommes J; Soehnlein O; Lutgens E; Shagdarsuren G; Togtokh A; Jacobs MJ; Fischer JW; Bernhagen J; Weber C; Schober A; Shagdarsuren E
Am J Pathol; 2014 Jul; 184(7):2123-33. PubMed ID: 24819959
[TBL] [Abstract][Full Text] [Related]
17. The interaction between C5a and both C5aR and C5L2 receptors is required for production of G-CSF during acute inflammation.
Bosmann M; Haggadone MD; Zetoune FS; Sarma JV; Ward PA
Eur J Immunol; 2013 Jul; 43(7):1907-13. PubMed ID: 23575697
[TBL] [Abstract][Full Text] [Related]
18. Complement C5A regulates prolabor mediators in human placenta.
Lappas M; Woodruff TM; Taylor SM; Permezel M
Biol Reprod; 2012 Jun; 86(6):190. PubMed ID: 22441801
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles.
Spillantini MG; Crowther RA; Goedert M
Acta Neuropathol; 1996 Jul; 92(1):42-8. PubMed ID: 8811124
[TBL] [Abstract][Full Text] [Related]
20. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system.
Gasque P; Singhrao SK; Neal JW; Götze O; Morgan BP
Am J Pathol; 1997 Jan; 150(1):31-41. PubMed ID: 9006319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
